JeanMarie Guenot is an experienced executive in the biotechnology and pharmaceutical industries. For over two decades, she has worked for both public and private companies. In her previous positions, she was responsible for business development, corporate & commercial development, venture capital, and project & alliance management. Currently, Guenot works as the president & chief executive officer of Amphivena Therapeutics. Dr. Guenot is charged with the duty of providing leadership to ensure that the company succeeds in its quest to develop bi-functional antibody therapies for cancer treatment. This technology involves using the body’s immune system to attack cancer cells. Amphivena Therapeutics was established in 2012. Over the years, it has secured funding from numerous sources. In the second quarter of 2015, the company received $9.7 million for funding its noble projects.
Dr. Guenot boasts of a successful career and great entrepreneurial skills. Before joining Amphivena, she worked for SKS Ocular, her own company. Her start-up business focused on dry AMD to develop therapies for macular degeneration, ocular inflammation, and glaucoma. She has also worked for Hoffmann-La Roche as the business advisor in Basel and Shanghai. At PDL BioPharm, she served as the vice president of corporate & business development. In this position, she oversaw licensing, alliance management, as well as mergers and acquisitions. The executive leader played an integral role in the negotiations that resulted in the creation of Biogen Idec-PDL 50:50 agreement. The deal saw the two companies co-develop and co-commercialize three Phase 2 cancer drug candidates. She also oversaw the licensing of ophthalmic indication for oncology therapy to Ophthotech. Dr. JeanMarie Guenot has extensive experience in the areas of autoimmune diseases, ophthalmic diseases, oncology, and cardiovascular diseases. In fact, as MarketWired explored, Dr. Guenot is working with Janssen on brand new medical breakthroughs.
Guenot’s career started at the Atlas Venture. She was responsible for managing the venture capital. Guenot focused on life science companies and managed to help many start-ups grow and become successful. Later, she switched from her business career and joined Preclinical R&D at Hoffmann-La Roche, as a principal scientist. In this position, she was involved in developing drugs for oncology, autoimmune diseases, inflammation, and metabolic diseases. Her physical and medical chemistry background has greatly contributed to her successful career. The focus of her training was in protein structure prediction, drug design, NRM refinement, and molecular dynamics. Dr. JeanMarie Guenot holds an MBA from Wharton School. She earned her Ph.D. from the esteemed University of California. Read more about where Jeanmarie plans on taking her company in the future through this article: Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies